LYEL

Lyell Immunopharma, Inc. (NASDAQ:LYEL) is a clinical-stage biotechnology company founded in 2018 and headquartered in South San Francisco, California. The company went public in June 2021 and specializes in developing novel T cell therapies for patients with solid tumors. Lyell focuses on overcoming the limitations of current cancer immunotherapies by reprogramming T cells to maintain their effectiveness against cancer over extended periods, addressing a critical challenge in oncology where T cells often become exhausted and lose their cancer-fighting capabilities.